IUPAC: methyl 2-phenyl-2-(piperidin-2-yl)acetate · MW 233.31 g/mol (freebase) · CAS 113-45-1 · HCl CAS 298-59-9
threo-Methylphenidate. Piperidine-ring phenylacetate ester · a pure catecholamine reuptake blocker, not a releaser. Brand/context names: Ritalin, Concerta, Focalin (d-isomer), Daytrana (patch), "kiddie coke", "vitamin R".
This is the single most important distinction on this page. Methylphenidate is a pure reuptake blocker — it is not a substrate and not a releaser. Amphetamine (#006) is transported into the terminal, collapses vesicular storage, and reverses DAT to pump dopamine out — carrier-mediated efflux with no upper ceiling. Methylphenidate does the opposite: it sits in the S1 central binding site and occludes the pore from the outside, like cocaine. It never enters the cell, never touches VMAT2, and never forces release. It simply stops the transporter from clearing dopamine and norepinephrine that neurons have already fired out on their own.
Methylphenidate binds the DAT S1 orthosteric site and locks the transporter in an outward-open, occluded conformation — the same pocket cocaine and WIN 35,428 occupy. Dopamine can no longer dock and be pulled back in.
The identical mechanism at NET (Ki 340–660 nM) raises synaptic and cortical norepinephrine. NET blockade in prefrontal cortex, where NET also clears dopamine, underlies much of the pro-cognitive ADHD effect.
Because reuptake blockade can only preserve dopamine that tonic/phasic firing already released, the synaptic rise is self-limiting. Amphetamine's releaser mechanism has no such brake — a key reason methylphenidate's dose–response is flatter.
Unlike amphetamines, methylphenidate does not deplete vesicles, does not generate cytoplasmic free dopamine, and does not drive reverse transport. This removes the oxidative/efflux limb thought to contribute to amphetamine neurotoxicity.
Mechanistically methylphenidate is a cocaine congener at DAT. What differs is kinetics: oral dosing gives slow striatal uptake and slow washout, blunting the euphoric spike. Insufflated or IV, that separation collapses and the profile becomes cocaine-like.
Serotonin is essentially untouched (SERT Ki ≈ 65 µM, >1000× weaker than DAT). Methylphenidate is a clean catecholaminergic agent — no direct serotonergic contribution, so classic serotonin syndrome is not its signature toxidrome.
The stereochemistry is not a footnote. Methylphenidate has two stereocentres; the marketed drug is the threo pair only (the erythro diastereomer is inactive and was removed). Within the threo pair, the d-threo (2R,2′R) enantiomer — dexmethylphenidate — is the eutomer, carrying essentially all the DAT activity (d-threo DAT Ki 16–25 nM), while l-threo (2S,2′S) is largely inert and is preferentially stripped out by first-pass hydrolysis. Racemic "Ritalin" is, pharmacodynamically, mostly its d-enantiomer by the time it reaches the brain.
Methylphenidate breaks the usual stimulant PK mold: it is not primarily a CYP substrate. Roughly 80% of a dose is cleared by carboxylesterase 1 (CES1), a high-capacity hepatic esterase that hydrolyses the methyl ester to ritalinic acid (α-phenyl-2-piperidineacetic acid) — a pharmacologically inactive, water-soluble carboxylic acid that is renally excreted. Oral bioavailability is low and highly variable (~11–52%) because of this extensive first-pass hydrolysis.
CES1 is stereoselective: it hydrolyses l-threo faster than d-threo, so the pharmacologically
active d-enantiomer is enriched in plasma after oral dosing. Genetic CES1 variants (e.g. the loss-of-function
G143E) sharply reduce clearance and raise exposure — a real source of interindividual response
and side-effect variability.
Metabolism cascade: A single dominant hydrolytic step accounts for the bulk of clearance — no active metabolites, minimal oxidative metabolism.
Because clearance runs through an esterase rather than CYP2D6/3A4, the classic amphetamine-type CYP interaction web (and the CYP2D6 poor-metabolizer risk) largely does not apply to methylphenidate. The relevant hepatic hazard is different: CES1 also hydrolyses ethyl esters, and when methylphenidate is taken with ethanol, CES1 catalyses transesterification to ethylphenidate, a longer-acting active metabolite, while raising d-methylphenidate levels — a real, common, and under-appreciated interaction.
Methylphenidate's DAT-preferring, NET-secondary blockade (DAT:NET Ki ≈ 34:340, roughly 10-fold DAT-selective) maps cleanly onto its catecholaminergic clinical profile: prefrontal signal-to-noise gains at therapeutic exposure, striatal reward engagement as dose and rate of rise climb. There is no direct serotonergic limb, so this section is dopamine and norepinephrine only.
At therapeutic oral doses, methylphenidate raises catecholamine tone in dorsolateral prefrontal cortex, strengthening D1 and α2A signaling that sharpens the signal-to-noise of working-memory and top-down attention circuits (the Arnsten "inverted-U"). This — not euphoria — is the substrate of its ADHD efficacy. In PFC, NET is the main clearance route for BOTH NE and DA, so NET blockade there boosts prefrontal dopamine even though the drug is DAT-preferring elsewhere.
In the nucleus accumbens and dorsal striatum, DAT blockade elevates extracellular dopamine. Clinically meaningful ADHD doses already occupy a large fraction of striatal DAT (PET shows >50% occupancy). What separates therapy from a high is the rate of rise: slow oral uptake produces a gentle plateau, while insufflated or IV routes produce a fast dopamine spike that is subjectively cocaine-like and strongly reinforcing.
NET blockade outside the CNS raises circulating and synaptic norepinephrine, driving the autonomic profile: tachycardia, raised blood pressure, appetite suppression, mydriasis, and reduced sleep. These are on-target consequences of the same reuptake blockade, and they are the basis of the cardiovascular cautions below rather than an idiosyncratic toxicity.
At supratherapeutic doses the firing-dependent ceiling is progressively overwhelmed by near-complete DAT occupancy plus behavioral arousal, and the profile shifts toward the classic high-dose stimulant syndrome: stereotypy/punding, anxiety, and — with sustained heavy use — stimulant psychosis. This is a quantitative escalation of the same blockade, not a new mechanism.
Evidence-based, non-moralistic. Risks are dose-, route-, and rate-dependent. Oral therapeutic use and crushed-for-insufflation/IV use are pharmacologically different animals.
| Target | Affinity (Ki) | Rel. | Mechanism |
|---|---|---|---|
|
DAT
Dopamine transporter (SLC6A3)
|
34 – 110 nM
d-threo: 16–25 nM
|
Reuptake blocker | |
|
NET
Norepinephrine transporter (SLC6A2)
|
340 – 660 nM
~10× weaker than DAT
|
Reuptake blocker | |
|
SERT
Serotonin transporter (SLC6A4)
|
~65,000 nM
>1000× weaker · negligible
|
Inactive |